Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases

Inclusion Criteria:

Primary lung cancer (any type) or dominant lung metastases from other primary cancers.
Patients must have either measurable or evaluable disease.
Karnofsky performance status ≥ 70%.
Greater than 18 years of age.
Life expectancy > 3 months.
3 week elapse from previous cytotoxic therapy (except for erlotinib or hormonal therapy, which can be ongoing) with side effects improved to grade 2 or less, and no prior radiotherapy to the lung.
Adequate organ function.
Treated brain metastases, if present, with toxicities improved to grade 2 or less.
Willingness and ability to sign a written informed consent.

Exclusion Criteria:

Prior radiation to the largest lesion in the lung.
Current pregnancy or breast-feeding.
Unwillingness or inability to practice contraception.
Renal insufficiency.
Comorbidities of grade 3 or greater.
Concurrent medical or psychiatric conditions as defined by the treating physician which would preclude safe performance of study procedures or compromise the ability of the patient to consent to study.